Evidence map›Paper›PMID 42265240›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026

Burden and causes of hearing loss among different genders and ages in China: a secondary analysis of the 2019 global burden of disease study.

Yiming Shen, Xunbei Shi, Gaogan Jia, Pei Zhou, Lichun Qiao, Feitian Li, Wenyan Li, Chunfu Dai

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Reply to the Comment on "Predicting recovery in Bell's Palsy: the impact of early rehabilitation and prognostic indicators".European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yiming Shen *Department of Otology and Skull Base Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China.
Xunbei Shi *Department of Otology and Skull Base Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China.
Gaogan Jia *Department of Otology and Skull Base Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China.
Pei Zhou *Department of Otology and Skull Base Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China.
Lichun QiaoSchool of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China.
Feitian LiDepartment of Otology and Skull Base Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China.
Wenyan Li *Department of Otology and Skull Base Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China.
Chunfu Dai *Department of Otology and Skull Base Surgery, Eye, Ear, Nose, and Throat Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China. cfdai66@126.com.ORCID http://orcid.org/0000-0002-6948-7289

Funding

National Natural Science Foundation of China No. 82171142 CFD
6 · The paper itself

Abstract

backgroundReliable national assessments of hearing loss are essential for evaluating their burden and developing public health policies. However, a comprehensive analysis specific to China has been lacking. Therefore, to estimate the burden of hearing loss in China, we described the national hearing loss burden by severity, cause, gender, and age in 2019.

methodsThis study conducted a secondary analysis using data from the Global Burden of Disease Study 2019. We provided national prevalence and years lived with disability (YLDs) counts by gender and age group, as well as the prevalence, crude rates, and age-standardized rates (ASRs) per 100,000 people for hearing loss of various severities and cause-specific hearing loss, with 95% uncertainty intervals (UIs).

findingsIn 2019, the prevalence of hearing loss in China was 426.5 million, and YLDs were 11.1 million. The total ASRs and total YLDs for all types of hearing loss per 100,000 people were 22,612 cases and 617.9, respectively. The burden of mild hearing loss was the most significant, followed by moderate, moderately severe, severe, and profound hearing loss. Age-related and other hearing loss were the primary causes of hearing loss, while otitis media was the secondary cause for mild and moderate hearing loss, and congenital defects were the secondary cause for more severe hearing loss. Individuals over 50 years of age experienced the highest prevalence of hearing loss, with peak prevalence in the 65-69 age group.

conclusionHearing loss presents a significant public health challenge in China. Although the causes of hearing loss are correlated with the severity of hearing impairment, age-related hearing loss can be mitigated through early prevention. Coordinated efforts are necessary at various levels to address this public health challenge.

Indexed as

Hearing LossAdolescentAdultAgedAged, 80 and overAge DistributionChildChild, PreschoolChinaCost of IllnessFemaleGlobal Burden of DiseaseHumansInfantMaleMiddle AgedAge-relatedChinaHearing loss

Identifiers

PMID42265240

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.